Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Advanced Manufacturing topic
No spam. Unsubscribe anytime.
FDA explains advanced manufacturing technology (AMT) designation and how sponsors can apply
Summary
FDA described the AMT designation program: applicants should show technology novelty and maturity, provide model‑drug developmental data and a precise context of use; the agency runs a 180‑day review and assigns a designated lead to facilitate adoption across product reviews.
Dr. Kimberly Schultz outlined the purpose and application process for FDA’s Advanced Manufacturing Technologies (AMT) designation, established by statute to incentivize adoption of novel manufacturing methods that ‘‘substantially improve’’ manufacturing while maintaining product quality.
Schultz said successful designation requests rest on two pillars: demonstrable novelty relative to existing industry practice, and sufficient maturity such that the technology is ready for IND‑level implementation. Requests should include a clear context of use (product class, dosage form) and a model‑drug dataset that shows developmental and manufacturing performance, including batch analyses and process characterization.
The agency’s review follows a 180‑day clock after a preliminary completeness check. Designated AMTs receive prioritized FDA interactions, a named FDA lead familiar with the technology, and are encouraged to use master files to streamline cross‑referencing as multiple sponsor applications adopt the AMT. Common reasons for denial include technologies judged not novel, inadequate model‑drug data or insufficient technology maturity.
Schultz recommended staged engagement: early exploratory meetings with FDA’s AMT team during technology development, formal designation requests when IND‑ready, and continued interactions through product‑specific PDUFA or IND meetings to facilitate adoption. She also noted the AMT program can be paired with later platform designations once processes are validated for commercial use.
For sponsors, the key takeaways were to document novelty clearly, provide representative model‑drug data aligned to the declared context of use, and anticipate questions on implementation, scale‑up, and CGMP readiness prior to designation submission.
